KLK3 and prostate carcinoma: The importance of effective biomarkers, particularly in the prostate cancer setting, is evident considering that prostate-specific antigen (PSA) screening has formed the bedrock of prostate cancer diagnosis for over 25 years—a test lacking in specificity—resulting in significant treatment related morbidities from overdiagnosis and overtreatment [93].